FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559965119> ?p ?o ?g. }

• W2559965119 abstract "Abstract Novel agents for MM treatment such as TAL, bortezomib and lenalidomide while offering higher rates of response and CR have lead to new side-effects, in particular peripheral neuropathy that is dose limiting in more than 40% of patients. We have investigated the toxicity and the effectivness of low doses of TAL as maintenance treatment in MM in order to minimize this harmful side-effect. METHODS: From October 1999, 54 pts (20 males/34 females) with advanced/relapsed MM (IgG-K 28; IgG-λ 11; IgA-K 8; IgA-λ 4; λ 2; K 1) were treated with TAL at 100 mg/day; if well tolerated, the dose could be increased to a maximum of 400 mg/day. 2 pts stopped treatment and weren’t valuables for response. 11 pts (20%) progressed and 5 (9%) reached only a stable disease/minimal response. 27 pts (50%) responded to treatment with 22 (81%) PR (> 50% of reduction of MC) and 5 (9%) CR. Somnolence and stypsis were seen in all pts but were reversible and treated with symptomatic drugs. In 17 pts (11 F, 6 M, median age 70 yrs) we observed a symptomatic neuropathy and we decided to reduce dosage at 100 mg dayly only for 10 days at month as MT. All other causes of neuropathies were excluded. We prospectively performed longitudinal neurological and nerve conduction study before and during TAL treatment every 3 months. Nerve conduction studies included recording of sensory and motor nerve action potential from surale, radial, ulnar, common peroneal and tibial nerves. We considered -p SNAP and Cmap amplitude for each nerve. Electromyography examination was performed in distal muscles of the limbs including denervation potentials and pattern of activation. RESULTS: In 2 out of 17 we found a mild distal sensory-motor neuropathy before TAL treatment. One referred paresthesia in the 8 months before the diagnosis of MM; the other one was asymptomatic and the diagnosis of neuropathy was made on the basis of clinical and electrophysiological data. The 2 pts with PN before TAL treatment showed a mild clinical and electrophysiological progression of the disease after 6 months of therapy. The first clinical symptoms were painful paresthesias and numbness in all pts. At neurological examination we found a symmetric distal polyneuropathy of sensory type with major evidence at lower limbs. Hypopallestesia and hyporeflexia at lower limbs were detected in all pts; in 3 there was areflexia of achillei reflexes. In 2 pts we found hyperesthesia a stock and gloves distribution. No pts showed motor deficits or cranial nerves impairments. In 12 out of 17 pts an axonal sensory-motor neuropathy was found; in 3 pts a pure sensitive neuropathy, more evident at lower limbs, was detected. In the subsequent 58 months follow-up evaluation, no progression of clinical and electrophysiological findings was demonstrated in the 17 pts. Two of them, however, had to discontinue TAL therapy for severe painful paresthesias. After a median of 8 months’ follow-up, 10/17 pts are alive (2–58 months) and in remission (2 CR and 8 PR); 5 pts showed a disease progression after a median therapy of 5 months (2–23 months) and two pts, who had achieved a PR, had to stop therapy because of severe neurotoxicity after 8 months of treatment (5–12 months). CONCLUSIONS: The incidence of TAL neuropathy is high and problematic, but the lower cumulative doses of this schedule appear to be less toxic and manageble also mainteining a high rate of response (58%)." @default.
• W2559965119 created "2016-12-16" @default.
• W2559965119 creator A5007973328 @default.
• W2559965119 creator A5018942065 @default.
• W2559965119 creator A5019665558 @default.
• W2559965119 creator A5046908926 @default.
• W2559965119 creator A5079913014 @default.
• W2559965119 creator A5084359235 @default.
• W2559965119 creator A5089235279 @default.
• W2559965119 date "2007-11-16" @default.
• W2559965119 modified "2023-10-18" @default.
• W2559965119 title "Peripheral Neuropathy (PN) in Multiple Myeloma (MM) Responder Patients during Maintenance Therapy with Low-Intermittent Doses of Thalidomide (TAL)." @default.
• W2559965119 doi "https://doi.org/10.1182/blood.v110.11.4829.4829" @default.
• W2559965119 hasPublicationYear "2007" @default.
• W2559965119 type Work @default.
• W2559965119 sameAs 2559965119 @default.
• W2559965119 citedByCount "0" @default.
• W2559965119 crossrefType "journal-article" @default.
• W2559965119 hasAuthorship W2559965119A5007973328 @default.
• W2559965119 hasAuthorship W2559965119A5018942065 @default.
• W2559965119 hasAuthorship W2559965119A5019665558 @default.
• W2559965119 hasAuthorship W2559965119A5046908926 @default.
• W2559965119 hasAuthorship W2559965119A5079913014 @default.
• W2559965119 hasAuthorship W2559965119A5084359235 @default.
• W2559965119 hasAuthorship W2559965119A5089235279 @default.
• W2559965119 hasConcept C126322002 @default.
• W2559965119 hasConcept C134018914 @default.
• W2559965119 hasConcept C141071460 @default.
• W2559965119 hasConcept C2776364478 @default.
• W2559965119 hasConcept C2776694085 @default.
• W2559965119 hasConcept C2777478702 @default.
• W2559965119 hasConcept C2778283404 @default.
• W2559965119 hasConcept C2779609412 @default.
• W2559965119 hasConcept C2779901536 @default.
• W2559965119 hasConcept C27924281 @default.
• W2559965119 hasConcept C29730261 @default.
• W2559965119 hasConcept C555293320 @default.
• W2559965119 hasConcept C71924100 @default.
• W2559965119 hasConcept C90924648 @default.
• W2559965119 hasConceptScore W2559965119C126322002 @default.
• W2559965119 hasConceptScore W2559965119C134018914 @default.
• W2559965119 hasConceptScore W2559965119C141071460 @default.
• W2559965119 hasConceptScore W2559965119C2776364478 @default.
• W2559965119 hasConceptScore W2559965119C2776694085 @default.
• W2559965119 hasConceptScore W2559965119C2777478702 @default.
• W2559965119 hasConceptScore W2559965119C2778283404 @default.
• W2559965119 hasConceptScore W2559965119C2779609412 @default.
• W2559965119 hasConceptScore W2559965119C2779901536 @default.
• W2559965119 hasConceptScore W2559965119C27924281 @default.
• W2559965119 hasConceptScore W2559965119C29730261 @default.
• W2559965119 hasConceptScore W2559965119C555293320 @default.
• W2559965119 hasConceptScore W2559965119C71924100 @default.
• W2559965119 hasConceptScore W2559965119C90924648 @default.
• W2559965119 hasLocation W25599651191 @default.
• W2559965119 hasOpenAccess W2559965119 @default.
• W2559965119 hasPrimaryLocation W25599651191 @default.
• W2559965119 hasRelatedWork W1533169501 @default.
• W2559965119 hasRelatedWork W1762081208 @default.
• W2559965119 hasRelatedWork W1986021912 @default.
• W2559965119 hasRelatedWork W2027275536 @default.
• W2559965119 hasRelatedWork W2044144069 @default.
• W2559965119 hasRelatedWork W2098422029 @default.
• W2559965119 hasRelatedWork W2146909642 @default.
• W2559965119 hasRelatedWork W2150885028 @default.
• W2559965119 hasRelatedWork W2374260719 @default.
• W2559965119 hasRelatedWork W2403269090 @default.
• W2559965119 isParatext "false" @default.
• W2559965119 isRetracted "false" @default.
• W2559965119 magId "2559965119" @default.
• W2559965119 workType "article" @default.